Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy Academic Article Article uri icon

Overview

MeSH Major

  • Cardiovascular Diseases
  • Diabetes Mellitus, Type 2
  • Hypertrophy, Left Ventricular

abstract

  • Baseline albuminuria is a powerful risk factor for CV events. Baseline albuminuria did not identify the group of patients with greatest benefit on losartan versus atenolol in LIFE. Reduction in albuminuria explained one-fifth of the benefits of losartan versus atenolol.

publication date

  • September 2004

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1097/00004872-200409000-00026

PubMed ID

  • 15311110

Additional Document Info

start page

  • 1805

end page

  • 11

volume

  • 22

number

  • 9